Trials / Completed
CompletedNCT06995001
Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics and immunogenicity of a single dose of SHR-2173 by subcutaneous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2173 | SHR-2173 injection dose 1； |
| DRUG | SHR-2173 ；Placebo | SHR-2173 injection dose 2 ；Pacebo dose 2 |
| DRUG | SHR-2173 ；Placebo | SHR-2173 injection dose 3 ；Pacebo dose 3 |
| DRUG | SHR-2173 ；Placebo | SHR-2173 injection dose 4 ；Pacebo dose 4 |
| DRUG | SHR-2173 ；Placebo | SHR-2173 injection dose 5 ；Pacebo dose 5 |
Timeline
- Start date
- 2024-04-28
- Primary completion
- 2024-11-28
- Completion
- 2024-11-28
- First posted
- 2025-05-29
- Last updated
- 2025-05-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06995001. Inclusion in this directory is not an endorsement.